Annexin 1 antibody
AssigneeQueen Mary & Westfield College, University of London
InventorsFulvio D'Acquisto, Mauro Perretti
Life of this patent
Estimating the term…
Abstract
The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
Claims13
An antibody or fragment thereof that binds human Anx-A1 having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
- VLCDR1 is KASENVVTYVS (SEQ ID NO:2)
- VLCDR2 is GASNRYT (SEQ ID NO:3)
- VLCDR3 is GQGYSYPYT (SEQ ID NO:4)
- VHCDR1 is GYTFTNYWIG (SEQ ID NO:5)
- VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6)
- VHCDR3 is WGLGYYFDY (SEQ ID NO:7)
- of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.
A hybridoma cell line which produces an antibody or fragment thereof that binds the human Anx-A1 protein having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising wherein the antibody comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
- VLCDR1 is KASENVVTYVS, (SEQ ID NO:2)
- VLCDR2 is GASNRYT, (SEQ ID NO:3)
- VLCDR3 is GQGYSYPYT, (SEQ ID NO:4)
- VHCDR1 is GYTFTNYWIG, (SEQ ID NO:5)
- VHCDR2 is DIYPGGDYTNYNEKFKG, and (SEQ ID NO:6)
- VHCDR3 is WGLGYYFDY (SEQ ID NO:7)
- of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.
Dependencies are inferred from the claim text.